Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 333 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Current Regimen Clear all
Completed Phase 3 Interventional Results available

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

NCT01967940
View directory record Official record
Conditions
HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017
View directory record Official record
Conditions
HIV Infection, Hyperlipidemia
Interventions
Atazanavir, current antiretroviral regimen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 11, 2026, 10:30 PM EDT
Completed No phase listed Observational

Long-term Follow-up of Spare the Nephron (STN) Patients

NCT01126333
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

NCT01276236
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 11, 2026, 10:30 PM EDT
Recruiting Phase 3 Interventional

Oxybutynin for Post-surgical Bladder Pain and Urgency

NCT03952299
View directory record Official record
Conditions
Overactive Bladder Syndrome, Neuropathic Bladder
Interventions
Oxybutynin Transdermal Patch, Oral Oxybutynin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
4 Years to 8 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 11, 2026, 10:30 PM EDT
Recruiting No phase listed Observational

Quantitative MRI for Myelofibrosis

NCT01973881
View directory record Official record
Conditions
Myelofibrosis
Interventions
T1 Weighted MRI (magnetic resonance imaging)
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

NCT00403481
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of the Cala ONE Device for Essential Tremor

NCT03152136
View directory record Official record
Conditions
Essential Tremor
Interventions
Cala ONE device
Device
Lead sponsor
Cala Health, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Oakland, California • Denver, Colorado • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Acupuncture Treatment for Patients Who Develop Arrhythmias in the Post-Operative Cardio-Thoracic Setting

NCT03525860
View directory record Official record
Conditions
Post-Operative Atrial Fibrillation, Acupuncture Therapy
Interventions
Acupuncture
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Sep 11, 2026, 10:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glutamate, Brain Connectivity and Duration of Untreated Psychosis

NCT02034253
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder
Interventions
Risperidone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
17 Years to 35 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Results available

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

NCT00735072
View directory record Official record
Conditions
HIV Infection
Interventions
Placebo, Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 11, 2026, 10:30 PM EDT
Completed No phase listed Observational

Therapeutic Research in Multiple Myeloma

NCT00572338
View directory record Official record
Conditions
Multiple Myeloma
Interventions
No drugs are involved
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
6,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 11, 2026, 10:30 PM EDT
Recruiting Phase 4 Interventional

The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

NCT05034432
View directory record Official record
Conditions
Arrythmia, Cardiomyopathies
Interventions
Intra-Op Prophylactic VT ablation, Conventional Management
Procedure · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Prehabilitation in Pancreatic Surgery

NCT03688867
View directory record Official record
Conditions
Pancreatic Resection, Preoperative Frailty
Interventions
Prehabilitation regimen
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Effect of Ramelteon on Smoking Abstinence

NCT02560324
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

NCT01004432
View directory record Official record
Conditions
Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions
Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

NCT04585737
View directory record Official record
Conditions
HIV I Infection
Interventions
Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
Drug
Lead sponsor
Charlotte-Paige Rolle, MD
Other
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

NCT00887653
View directory record Official record
Conditions
HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients

NCT01624948
View directory record Official record
Conditions
BK Virus Infection
Interventions
Everolimus, Mycophenolic acid dose reduction
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

NCT02502149
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 11, 2026, 10:30 PM EDT
Withdrawn Phase 4 Interventional

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

NCT00510627
View directory record Official record
Conditions
Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions
Radiofrequency Ablation (RFA), Chemotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 11, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

NCT04161495
View directory record Official record
Conditions
Factor VIII Deficiency
Interventions
efanesoctocog alfa (BIVV001)
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
12 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 11, 2026, 10:30 PM EDT
Recruiting Not applicable Interventional

Transvaginal Electrical Stimulation for Myofascial Pelvic Pain

NCT05354869
View directory record Official record
Conditions
Myofascial Pelvic Pain
Interventions
Urostym, Standard care
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 11, 2026, 10:30 PM EDT